Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.5K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.5K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8<sup>+</sup> T cells in persons with previous COVID-19.

Nature immunology·2023
Same author

Honokiol ameliorates angiotensin II-induced cardiac hypertrophy by promoting dissociation of the Nur77-LKB1 complex and activating the AMPK pathway.

Journal of cellular and molecular medicine·2023
Same author

miR-HCC2 suppresses hepatitis B virus replication by inhibiting the activity of the enhancer I/X promoter.

Archives of virology·2023
Same author

Neuroimaging-based classification of PTSD using data-driven computational approaches: A multisite big data study from the ENIGMA-PGC PTSD consortium.

NeuroImage·2023
Same author

Genomic Epidemiology of Treponema pallidum and Circulation of Strains With Diminished tprK Antigen Variation Capability in Seattle, 2021-2022.

The Journal of infectious diseases·2023
Same author

SALL1 promotes proliferation and metastasis and activates phosphorylation of p65 and JUN in colorectal cancer cells.

Pathology, research and practice·2023
Same journal

Farnesoid X receptor blockade attenuates morphological damage, intestinal secretion, and prevents mucus loss induced by SARS-CoV-2 spike protein in the mouse intestine.

The Journal of pharmacy and pharmacology·2026
Same journal

Therapeutic strategies of traditional Chinese medicine for chronic heart failure: from active ingredients to herbal formulations.

The Journal of pharmacy and pharmacology·2026
Same journal

Norisoboldine suppresses epithelial-mesenchymal transition in colorectal cancer by simultaneously inhibiting the CXCR4/CXCR7 chemokine receptors and the JAK/STAT3 signaling pathway.

The Journal of pharmacy and pharmacology·2026
Same journal

Development, characterization, and therapeutic evaluation of uniform dezocine-loaded PLGA microspheres for sustained analgesia and cognitive protection.

The Journal of pharmacy and pharmacology·2026
Same journal

Phytochemical constituents, biological activities, toxicological profiles, and current applications of Muntingia calabura L.: an updated review.

The Journal of pharmacy and pharmacology·2026
Same journal

Uterine relaxant effects of Ageratum conyzoides essential oil: influence of hormonal status and calcium modulation.

The Journal of pharmacy and pharmacology·2026
See all related articles

Related Experiment Video

Updated: Nov 12, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.4K

Propofol suppresses osteosarcoma cell function by regulating FOXO1/TUSC7.

Xinhua Huang1,2, Jing Liu2, Hong Xie1

  • 1Department of Anaesthesiology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, Jiangsu, China.

The Journal of Pharmacy and Pharmacology
|March 16, 2021
PubMed
Summary
This summary is machine-generated.

Propofol, an anesthetic, inhibits osteosarcoma cell growth, migration, and invasion. It achieves this by activating the FOXO1/TUSC7 pathway, which downregulates AKT/GSK3β signaling.

Keywords:
AKT/GSK3βFOXO1LncRNA TUSC7osteosarcomapropofol

More Related Videos

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.1K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.4K

Related Experiment Videos

Last Updated: Nov 12, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.4K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.1K
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.4K

Area of Science:

  • Oncology
  • Anesthesiology
  • Molecular Biology

Background:

  • Propofol exhibits anticancer properties across various malignancies.
  • The specific role of propofol in osteosarcoma remains largely uncharacterized.

Purpose of the Study:

  • To investigate the effects of propofol on osteosarcoma.
  • To elucidate the underlying molecular mechanisms of propofol's action in osteosarcoma.

Main Methods:

  • Osteosarcoma cell proliferation, migration, and invasion were assessed using MTT, wound healing, and Transwell assays.
  • Luciferase reporter assays and chromatin immunoprecipitation were employed to determine the interaction between FOXO1 and TUSC7.

Main Results:

  • Propofol significantly reduced proliferation, migration, and invasion in U2OS osteosarcoma cells.
  • Propofol enhanced TUSC7 expression via FOXO1, leading to AKT/GSK3β pathway inactivation.
  • This mechanism suppressed osteosarcoma cell proliferation, migration, and invasion.

Conclusions:

  • Propofol exerts an inhibitory effect on osteosarcoma cell proliferation, migration, and invasion.
  • The FOXO1/TUSC7 axis mediates propofol's anti-osteosarcoma effects by regulating AKT/GSK3β signaling.